In October, InBio had a big party in downtown Charlottesville to celebrate our history, successes and achievements over the past 25 years. And we thank you, our customers (some of whom have been with us all that time for your support on our journey.
Here is a brief synopsis of InBio‘s history:
InBio (formerly Indoor Biotechnologies), started out manufacturing ELISA reagent kits for researchers and for allergen manufacturers, which became widely adopted as standards for allergen measurements. This was followed by purified allergens, the Ventia™ rapid test for dust mites, the Multiplex Array for Indoor Allergens (MARIA®) and a suite of services for the pharma, industrial hygiene and consumer products industries.
An important goal was to remain at the cutting edge of research. Over the past 25 years, InBio has authored or co-authored ~150 publications on allergen structure, standardization, immune response, and environmental exposures in relation to allergic diseases. Dr. Anna Pomés, multi-center research team have determined 35 structures of allergen and allergen/antibody complexes, which has been supported since 2009 by an R01 grant from the National Institute for Allergy and Infectious Diseases.
Starting out, we had a pragmatic approach to business – just do it! We capitalized on demand by delivering quality products and services on time and by ensuring that our manufacturing supply could meet demand.
We learned that quality standards were beneficial and were thrilled to receive ISO accreditations for purified allergen manufacturing and for MARIA® services. Above all, we learned that business success, as in life, is about building synergistic relationships, partnerships and communities that work for the common good.
With our new name, logo and marketing materials, InBio is embracing the future, putting our scientific expertise in action and collaborating with companies worldwide to develop innovative diagnostic and therapeutic products for the benefit of those who suffer from allergy. “Research Made Real” is our commitment to work pro-actively with researchers and companies to provide the knowledge and authentic data for pre-clinical studies and for new product launches: to solve problems and t overcome real-world challenges.
InBio embraces evidence-based molecular approaches to research and development. InBio is pioneering CRISPR-based gene editing for cat allergy. We are excited to introduce transformational new technologies, including ELISA 2.0, MARIA® for Foods, human IgE monoclonal antibodies to inhaled and food allergens, and integrated mass spectrometry services. As a biomanufacturing company, we produce a comprehensive range of purified allergens and other biologics.
InBio’s UK site offers state-of-the art consumer product testing in its environmental testing suite and is also developing Apollo, a novel air sampling device. All these tools work synergistically to meet our customers’ needs.
InBio has invested heavily in laboratory space and facilities over the past 25 years, with a focus on form, function, and aesthetics. Cool spaces, including art galleries and meeting areas for our employees to enjoy. Currently, we are expanding our US facility in Charlottesville to accommodate tissue culture and manufacturing space for ELISA 2.0, including a Hamilton liquid handling robot.
Finally, InBio’s success over the past 25 years is testament to the commitment and dedication of our employees, many of whom have been on this journey with us for 10, 15, 20 or more years. These are the scientists, technicians and managers that take your calls, produce products, implement the science and solve problems. They exemplify InBio’s core values of trust, integrity, leadership, commitment to excellence and communication. And it’s so much fun to work with these folks every day!
In celebration, with thanks,
Martin D. Chapman, PhD
President & CEO